Recent News

• 03.20.2025 - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
• 03.20.2025 - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
• 03.17.2025 - vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
• 12.04.2024 - vTv Therapeutics Inc. at 7th Annual Evercore HealthCONx Conference
• 12.02.2024 - vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
• 12.02.2024 - vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
• 11.12.2024 - vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
• 11.12.2024 - vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

Recent Filings

• 03.17.2025 - 8-K Current report
• 03.17.2025 - EX-99.1 EX-99.1
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 8-K Current report
• 01.13.2025 - EX-99.1 EX-99.1
• 01.13.2025 - 8-K Current report
• 12.06.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.06.2024 - 4 Statement of changes in beneficial ownership of securities
• 11.19.2024 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors